Nucleix Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
70
- Latest Deal Type
-
Series E
- Latest Deal Amount
-
$77M
- Investors
-
13
Nucleix General Information
Description
Developer of liquid biopsy technology designed for early-stage and recurring cancer detection. The company's technology utilizes PCR-based epigenetics and machine learning algorithms to identify DNA methylation patterns in urine and blood samples, enabling healthcare operators and patients with non-invasive diagnostic tests that deliver objective numerical results for bladder and lung cancer monitoring.
Contact Information
Website
www.nucleix.comCorporate Office
- 3 Pekeris Street
- Rehovot 7670203
- Israel
Corporate Office
- 3 Pekeris Street
- Rehovot 7670203
- Israel
Nucleix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series E) | 01-Dec-2021 | $77M | Completed | Product Development | ||
| 6. Later Stage VC | 01-Mar-2021 | Completed | Product Development | |||
| 5. Grant | 30-Jul-2018 | Completed | Pre-Clinical Trials | |||
| 4. Later Stage VC (Series B) | 23-May-2016 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 22-Mar-2016 | Completed | Pre-Clinical Trials | |||
| 2. Later Stage VC (Series A) | 12-May-2014 | $5.4M | $8.4M | Completed | Pre-Clinical Trials | |
| 1. Angel (individual) | $3M | $3M | Completed | Startup |
Nucleix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series AA3 | ||||||||
| Series AA2 | ||||||||
| Series AA1 | ||||||||
| Ordinary C | ||||||||
| Ordinary B | 950,000 | $1.12 | $1.12 | 1x | $1.12 | 3.04% | ||
| Ordinary A | 900,000 | $1.12 | $1.12 | 1x | $1.12 | 2.88% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Nucleix Comparisons
Industry
Financing
Details
Nucleix Competitors (37)
One of Nucleix’s 37 competitors is Predicine, a Venture Capital-Backed company based in Hayward, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Predicine | Venture Capital-Backed | Hayward, CA | ||||
| Mindera Health | Venture Capital-Backed | Vista, CA | ||||
| Fluxion (Diagnostic Equipment) | Formerly VC-backed | Alameda, CA | ||||
| Vortex Biosciences | Venture Capital-Backed | Manchester, United Kingdom | ||||
| OncoDNA | Venture Capital-Backed | Gosselies, Belgium |
Nucleix Patents
Nucleix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025141580-A1 | Methods for preparing dna sequencing libraries | Inactive | 31-Dec-2023 | ||
| WO-2025097008-A2 | Mitochondrial dna intrinsic controls for use in msre-dependent dna methylation analysis | Inactive | 01-Nov-2023 | ||
| WO-2025097008-A3 | Mitochondrial dna intrinsic controls for use in msre-dependent dna methylation analysis | Inactive | 01-Nov-2023 | ||
| AU-2024331615-A1 | Fragmentomics-based plasma separation assays | Pending | 28-Aug-2023 | ||
| EP-4771179-A1 | Fragmentomics-based plasma separation assays | Pending | 28-Aug-2023 | C12Q1/686 |
Nucleix Signals
Nucleix Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BlackRock | Asset Manager | Minority | ||
| Gefen Capital | Venture Capital | Minority | ||
| Mirae Asset Capital | Venture Capital | Minority | ||
| Sands Capital | Growth/Expansion | Minority | ||
| LAV (Lilly Asia Fund) | Corporate Venture Capital | Minority |
Nucleix FAQs
-
When was Nucleix founded?
Nucleix was founded in 2008.
-
Where is Nucleix headquartered?
Nucleix is headquartered in Rehovot, Israel.
-
What is the size of Nucleix?
Nucleix has 70 total employees.
-
What industry is Nucleix in?
Nucleix’s primary industry is Diagnostic Equipment.
-
Is Nucleix a private or public company?
Nucleix is a Private company.
-
What is the current valuation of Nucleix?
The current valuation of Nucleix is .
-
What is Nucleix’s current revenue?
The current revenue for Nucleix is .
-
How much funding has Nucleix raised over time?
Nucleix has raised $143M.
-
Who are Nucleix’s investors?
BlackRock, Gefen Capital, Mirae Asset Capital, Sands Capital, and LAV (Lilly Asia Fund) are 5 of 13 investors who have invested in Nucleix.
-
Who are Nucleix’s competitors?
Predicine, Mindera Health, Fluxion (Diagnostic Equipment), Vortex Biosciences, and OncoDNA are some of the 37 competitors of Nucleix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process